Prelude Therapeutics Inc (PRLD) 뉴스

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients...

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq:...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2...

Form 8-K - Current report

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients...

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

WILMINGTON, Del., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD...

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

-  Encouraging signs of anti-tumor activity including objective responses observed in patients with...

Form 8-K - Current report